A476060 Share Price Performance
Recent A476060 News & Updates
No updates
Onconic Therapeutics Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -285.76
- Gross Margin
- 99.98%
- Net Profit Margin
- -13.93%
- Debt/Equity Ratio
- 0%
Onconic Therapeutics Inc. Competitors
About A476060
- Founded
- 2020
- Employees
- n/a
- CEO
- WebsiteView website
Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -2.5%
- 3 Months: 19.7%
- 1 Year: 13.3%
- Year to Date: 27.4%
Over the last 7 days, the market has dropped 2.5%, driven by a pullback of 8.3% in the Financials sector. As for the longer term, the market has actually risen by 13% in the last year. Looking forward, earnings are forecast to grow by 22% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading